Our lead product candidate, FavId, is an active immunotherapy for the treatment of indolent B-cell non-Hodgkin's lymphoma. FavId entered a pivotal Phase 3 clinical trial in July of 2004.

We are focused on the research, development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. Favrille was founded in 2000 by Drs. Bob Shopes and Dan Gold. We have been funded through sales of preferred stock totaling $77 million. We have completed enrollment in two Phase II clinical trials and entered a pivotal Phase III clinical trial for patients with follicular B-cell non-Hodgkin's lymphoma in July of 2004.

The Company's near term goal is to show that FavId- (Favrille's patient-specific therapeutic vaccine for low grade, follicular, B-cell non-Hodgkin's lymphoma (NHL)) is safe, effective and commercially viable. In support of this goal are promising results from a number of clinical studies by academic groups demonstrating the potential for long-term clinical remissions from this disease using a therapeutic vaccine as well as the Company's recent clinical results in relapsed patients. FavId™ is created following the identification, production and manipulation of tumor-specific "idiotype" proteins. Following presentation of these idiotype proteins to the patient in the context of a strong immune stimulating agent, KLH, most patients mount an idiotype-specific immune response that appears capable of destroying tumor cells. The Company has conducted two Phase II clinical studies in the U.S. in patients with follicular B-cell NHL.